US2013065874A1PendingUtilityA1

Methods for treating intrapulmonary infections

46
Individually held — no corporate assignee on recordPriority: Sep 9, 2011Filed: Sep 7, 2012Published: Mar 14, 2013
Est. expirySep 9, 2031(~5.1 yrs left)· nominal 20-yr term from priority
Inventors:Gurudatt ChandorkarJennifer A. HuntingtonTara ParsonsObiamiwe C. Umeh
A61P 31/04A61K 9/0019A61K 31/431A61K 31/546A61K 9/007Y02A50/30
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane.

Claims

exact text as granted — not AI-modified
1 . A method of treating an intrapulmonary infection comprising the step of intravenously administering about every 8 hours to a subject in need thereof a pharmaceutical composition comprising 3.0 g of ceftolozane. 
     
     
         2 . The method of  claim 1 , wherein the pharmaceutical composition further comprises tazobactam. 
     
     
         3 . The method of  claim 2 , wherein the pharmaceutical composition comprises ceftolozane and tazobactam and the infection comprises Gram-negative bacteria. 
     
     
         4 . A method of treating an intrapulmonary infection comprising the step of administering a therapeutically effective amount of a pharmaceutical composition comprising ceftolozane. 
     
     
         5 . The method of  claim 1 , wherein the intrapulmonary infection includes an infection in the lung. 
     
     
         6 . The method of  claim 1 , wherein the intrapulmonary infection is pneumonia. 
     
     
         7 . The method of  claim 1 , wherein the intrapulmonary infection is nosocomial pneumonia. 
     
     
         8 . The method of  claim 1 , wherein the pharmaceutical composition is parenterally administered. 
     
     
         9 . The method of  claim 1 , wherein the pharmaceutical composition is intravenously administered. 
     
     
         10 . The method of  claim 1 , wherein the pharmaceutical composition is intravenously administered about once every 8 hours as an infusion. 
     
     
         11 . The method of  claim 10 , wherein the pharmaceutical composition is intravenously administered as a 60-minute infusion. 
     
     
         12 . The method of  claim 1 , wherein the infection comprises  Pseudomonas aeruginosa,  Enterobacteriaceae, or a combination thereof. 
     
     
         13 . The method of  claim 1 , wherein the infection comprises  Pseudomonas aeruginosa.    
     
     
         14 . The method of  claim 1 , wherein the infection comprises a pathogen with minimum inhibitory concentration for ceftolozane and tazobactam of ≦8 μg/ml. 
     
     
         15 . The method of  claim 1 , wherein the infection comprises a pathogen with minimum inhibitory concentration for ceftolozane of ≦8 μg/ml. 
     
     
         16 . A method of providing tazobactam or ceftolozane in the epithelial lining fluid of a subject in an amount effective to treat an intrapulmonary infection, comprising the step of intravenously administering to the subject a pharmaceutical composition comprising ceftolozane. 
     
     
         17 . The method of  claim 16 , wherein the pharmaceutical composition further comprises tazobactam and the pharmaceutical composition is CXA-201. 
     
     
         18 . The method of  claim 1 , wherein the method comprises administering about 1.5 g of ceftolozane and tazobactam every 8 hours. 
     
     
         19 . The method of  claim 1 , wherein the amount of the ceftolozane in the epithelial lining fluid of the subject effective to treat an intrapulmonary infection is at least about 8 μg/ml. 
     
     
         20 . The method of  claim 1 , wherein the ELF concentration of ceftolozane in the ELF reaches at least about 8 μg/ml after administration of the pharmaceutical composition. 
     
     
         21 . The method of  claim 1 , wherein the subject is a human having, or believed to be at risk of having, nosocomial pneumonia. 
     
     
         22 . The method of  claim 21 , wherein the patient has ventilator acquired pneumonia or hospital acquired pneumonia. 
     
     
         23 . The method of  claim 1 , wherein the treatment comprises administering ceftolozane every 8 hours.

Join the waitlist — get patent alerts

Track US2013065874A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.